ELI LILLY AND COMPANY (NYSE: LLY)

ELI LILLY AND COMPANY

NYSE: LLY (Eli Lilly and Company)

最近更新时间: 5天之前, 8:07AM

737.67

15.10 (2.09%)

加入群组

前收盘价格	722.57
收盘价格	725.00
成交量	6,099,688
平均成交量 (3个月)	4,203,396
市值	662,232,891,392

市盈率 (P/E TTM)	59.88
预期市盈率 (P/E Forward)	36.76
价格/销量 (P/S)	14.64
股市价格/股市净资产 (P/B)	45.23

52周波幅	677.09 (-8%) — 972.53 (31%)
利润日期	7 Aug 2025
股息率 (DY TTM)	0.56%

市场趋势

		短期	中期
行业	Drug Manufacturers - General (US)	看跌	混合的
	Drug Manufacturers - General (全球的)	看跌	混合的
股票	Eli Lilly and Company	看跌	看涨

AIStockmoo 评分

0.4

分析师共识	1.5
内部交易活动	-1.5
价格波动	4.5
技术平均移动指标	0.0
技术振荡指标	-2.5
平均	0.40

相关股票

股票	市值	DY	P/E（TTM）	P/B
LLY	662 B	0.56%	59.88	45.23
NVO	328 B	2.21%	20.45	13.27
NVS	227 B	3.52%	18.01	5.80
MRK	191 B	4.17%	11.03	4.52
JNJ	372 B	2.40%	17.21	4.73
ABBV	321 B	3.51%	77.36	229.94

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
部门	Healthcare
行业	Drug Manufacturers - General
投资方式	Large Growth
内部持股比例	0.16%
机构持股比例	83.51%

所有权

姓名	日期	持有股份
Lilly Endowment Inc	31 Mar 2025	96,016,978

52周波幅	677.09 (-8%) — 972.53 (31%)
目标价格波幅	700.00 (-5%) — 1,124.00 (-99%)
高	1,124.00 (Morgan Stanley, 52.37%)	购买
中	951.50 (28.99%)
低	700.00 (HSBC, -5.11%)	卖出
平均值	944.17 (27.99%)
总计	5 购买, 1 卖出
平均价格@调整类型	793.79

公司	日期	目标价格	调整类型	价格@调整类型
UBS	02 May 2025	1,050.00 (42.34%)	购买	823.62
HSBC	28 Apr 2025	700.00 (-5.11%)	卖出	877.29
Cantor Fitzgerald	22 Apr 2025	975.00 (32.17%)	购买	827.54
Guggenheim	14 Apr 2025	928.00 (25.80%)	购买	754.35
Morgan Stanley	09 Apr 2025	1,124.00 (52.37%)	购买	753.71
Goldman Sachs	08 Apr 2025	888.00 (20.38%)	购买	726.24

名称	平均购买 ($)	平均卖出 ($)	总净额	总净值 ($)
ZAKROWSKI DONALD A	-	725.22	-1,000	-725,220
累积净数量				-1,000
累积净值 ($)				-725,220
累积平均购买 ($)				-
累积平均卖出 ($)				725.22

名称	持有人	日期	类型	数量	价格	价值 ($)
ZAKROWSKI DONALD A	职员	27 May 2025	自动卖出 (-)	1,000	725.22	725,220

日期	类型	细节
02 Jun 2025	公告	Lilly presents first clinical data for its investigational, next-generation FRα targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting
02 Jun 2025	公告	Lilly to participate in Goldman Sachs 46th Annual Global Health Care Conference
29 May 2025	公告	Lilly announces details of presentations at American Diabetes Association's (ADA) 85th Scientific Sessions
27 May 2025	公告	Lilly to expand its pain pipeline with acquisition of SiteOne Therapeutics
22 May 2025	公告	Lilly announces details of presentations at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
21 May 2025	CNBC	Cigna announces new deal for copay caps on Eli Lilly and Novo Nordisk weight loss drugs
21 May 2025	公告	Lilly's Kisunla (donanemab) receives marketing authorization in Australia for the treatment of early symptomatic Alzheimer's disease
19 May 2025	CNBC	Novo Nordisk is betting on a CEO shake-up to regain its weight loss drug edge over Eli Lilly
12 May 2025	CNBC	Trump's plan to slash drug prices may struggle to get off the ground – here's what to know
12 May 2025	CNBC	Trump signs order aiming to cut some U.S. drug prices to match lower ones abroad
11 May 2025	公告	Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of Medicine
09 May 2025	公告	Lilly plans to expand Purdue University collaboration with up to a $250 million investment to accelerate pharmaceutical innovation
08 May 2025	公告	Lilly announces transitions in executive leadership
05 May 2025	公告	Lilly declares second-quarter 2025 dividend
05 May 2025	CNBC	Trump signs order to boost domestic drug manufacturing as pharma tariffs loom
05 May 2025	公告	Scribe Therapeutics to Highlight In Vivo CRISPR-based Genome Editing Data for Duchenne Muscular Dystrophy at ASGCT 2025, in Addition to Joint Presentation with Prevail Therapeutics, a Part of Lilly’s Gene Therapy Division
02 May 2025	公告	Lilly to participate in Bank of America Securities 2025 Healthcare Conference
01 May 2025	CNBC	Eli Lilly sales soar 45% on weight loss drug demand, but drugmaker cuts profit outlook after cancer treatment deal
01 May 2025	CNBC	CVS to boost access to Novo Nordisk's weight loss treatment Wegovy for patients on its drug plans
01 May 2025	CNBC	Eli Lilly CEO says company can help 'respond' to national security concerns around essential drugs as tariffs loom
01 May 2025	公告	Lilly reports first-quarter 2025 financial results and highlights pipeline momentum
29 Apr 2025	CNBC	Novo Nordisk opens weight loss drug Wegovy to telehealth; Hims & Hers shares rocket 23%
29 Apr 2025	公告	Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors
28 Apr 2025	公告	Scribe Achieves Milestone for In Vivo Program in Collaboration with Prevail Therapeutics, a part of Lilly’s Gene Therapy Division, and Announces ASGCT Joint Presentation on Self-Inactivating AAV Technology for Neurological and Neuromuscular Disorders
25 Apr 2025	CNBC	Novo Nordisk scores major legal win that bars many compounded versions of Wegovy, Ozempic
24 Apr 2025	CNBC	Corporate America shelled out millions for Trump's inauguration. Now he's upending many of their businesses
23 Apr 2025	CNBC	Eli Lilly sues four telehealth sites selling compounded Zepbound, Mounjaro
17 Apr 2025	CNBC	Eli Lilly’s weight loss pill succeeds in first late-stage trial on diabetes patients; shares jump 14%
17 Apr 2025	公告	Lilly confirms date and conference call for first-quarter 2025 financial results announcement
17 Apr 2025	公告	Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial
14 Apr 2025	CNBC	Pfizer scraps daily weight loss pill after liver injury in one patient
11 Apr 2025	CNBC	Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
09 Apr 2025	CNBC	Pharmaceutical stocks rise as Trump pauses tariffs but not for China
01 Apr 2025	CNBC	Eli Lilly sues two pharmacies making copycat Zepbound, Mounjaro
30 Mar 2025	公告	Lilly's lepodisiran reduced levels of genetically inherited heart disease risk factor, lipoprotein(a), by nearly 94% from baseline at the highest tested dose in adults with elevated levels
29 Mar 2025	CNBC	Novo Nordisk's diabetes pill slashes risk of cardiovascular complications by 14% after four years
27 Mar 2025	公告	LillyDirect platform expands to facilitate access to Alzheimer's disease care
26 Mar 2025	公告	Direxion Expands Single Stock Leveraged & Inverse ETF Lineup for Exposure to Eli Lilly & Palo Alto Networks
25 Mar 2025	公告	Lilly announces details of presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting
25 Mar 2025	公告	Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company
24 Mar 2025	CNBC	Eli Lilly will soon release key data on its weight loss pill. Here's why it could be a game-changer
22 Mar 2025	CNBC	Zepbound copycats remain online despite FDA ban
18 Mar 2025	公告	Lexarias' DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound
08 Mar 2025	公告	Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study
07 Mar 2025	公告	Lilly's EBGLYSS® (lebrikizumab-lbkz) single monthly maintenance injection achieved completely clear skin at three years in half of patients with moderate-to-severe atopic dermatitis
显示更多

股息率 (DY TTM)	0.56%
5年平均股息收益率	1.10%
股息支付比率	44.41%
预计下次股息支付	Sep 2025

除息日	公告日期	支付日期	详情
14 Feb 2025	09 Dec 2024	10 Mar 2025	1.5 现金
15 Nov 2024	28 Oct 2024	10 Dec 2024	1.3 现金
15 Aug 2024	24 Jun 2024	10 Sep 2024	1.3 现金
15 May 2024	06 May 2024	10 Jun 2024	1.3 现金
14 Feb 2024	08 Dec 2023	08 Mar 2024	1.3 现金
14 Nov 2023	01 Nov 2023	08 Dec 2023	1.13 现金
14 Aug 2023	26 Jun 2023	08 Sep 2023	1.13 现金
12 May 2023	01 May 2023	09 Jun 2023	1.13 现金
14 Feb 2023	12 Dec 2022	10 Mar 2023	1.13 现金
14 Nov 2022	17 Oct 2022	09 Dec 2022	0.98 现金
12 Aug 2022	27 Jun 2022	09 Sep 2022	0.98 现金
13 May 2022	02 May 2022	10 Jun 2022	0.98 现金
14 Feb 2022	13 Dec 2021	10 Mar 2022	0.98 现金
12 Nov 2021	18 Oct 2021	10 Dec 2021	0.85 现金
12 Aug 2021	29 Jun 2021	10 Sep 2021	0.85 现金
13 May 2021	03 May 2021	10 Jun 2021	0.85 现金
11 Feb 2021	14 Dec 2020	10 Mar 2021	0.85 现金
12 Nov 2020	19 Oct 2020	10 Dec 2020	0.74 现金
13 Aug 2020	15 Jul 2020	10 Sep 2020	0.74 现金
14 May 2020	04 May 2020	10 Jun 2020	0.74 现金
13 Feb 2020	16 Dec 2019	10 Mar 2020	0.74 现金
14 Nov 2019	22 Oct 2019	10 Dec 2019	0.645 现金
14 Aug 2019	20 Jun 2019	10 Sep 2019	0.645 现金
16 May 2019	07 May 2019	10 Jun 2019	0.645 现金
14 Feb 2019	19 Dec 2018	08 Mar 2019	0.645 现金
14 Nov 2018	16 Oct 2018	10 Dec 2018	0.5625 现金
14 Aug 2018	19 Jun 2018	10 Sep 2018	0.5625 现金
16 May 2018	07 May 2018	08 Jun 2018	0.5625 现金
14 Feb 2018	11 Dec 2017	09 Mar 2018	0.5625 现金
14 Nov 2017	16 Oct 2017	08 Dec 2017	0.52 现金
11 Aug 2017	19 Jun 2017	08 Sep 2017	0.52 现金
11 May 2017	01 May 2017	09 Jun 2017	0.52 现金
13 Feb 2017	12 Dec 2016	10 Mar 2017	0.52 现金
10 Nov 2016	17 Oct 2016	09 Dec 2016	0.51 现金
11 Aug 2016	20 Jun 2016	09 Sep 2016	0.51 现金
11 May 2016	02 May 2016	10 Jun 2016	0.51 现金
10 Feb 2016	08 Dec 2015	10 Mar 2016	0.51 现金
10 Nov 2015	19 Oct 2015	10 Dec 2015	0.5 现金
12 Aug 2015	15 Jun 2015	10 Sep 2015	0.5 现金
14 May 2015	04 May 2015	10 Jun 2015	0.5 现金
11 Feb 2015	15 Dec 2014	10 Mar 2015	0.5 现金
12 Nov 2014	20 Oct 2014	10 Dec 2014	0.49 现金
13 Aug 2014	16 Jun 2014	10 Sep 2014	0.49 现金
13 May 2014	05 May 2014	10 Jun 2014	0.49 现金
12 Feb 2014	16 Dec 2013	10 Mar 2014	0.49 现金
13 Nov 2013	21 Oct 2013	10 Dec 2013	0.49 现金
13 Aug 2013	18 Jun 2013	10 Sep 2013	0.49 现金
14 May 2013	03 May 2013	10 Jun 2013	0.49 现金
13 Feb 2013	17 Dec 2012	08 Mar 2013	0.49 现金
13 Nov 2012	15 Oct 2012	10 Dec 2012	0.49 现金
13 Aug 2012	19 Jun 2012	10 Sep 2012	0.49 现金
13 Feb 2012	12 Dec 2011	09 Mar 2012	0.49 现金
10 Nov 2011	17 Oct 2011	09 Dec 2011	0.49 现金
11 Aug 2011	20 Jun 2011	09 Sep 2011	0.49 现金
11 May 2011	18 Apr 2011	10 Jun 2011	0.49 现金
11 Feb 2011	13 Dec 2010	10 Mar 2011	0.49 现金
10 Nov 2010	18 Oct 2010	10 Dec 2010	0.49 现金
11 Aug 2010	21 Jun 2010	10 Sep 2010	0.49 现金
12 May 2010	19 Apr 2010	10 Jun 2010	0.49 现金
10 Feb 2010	14 Dec 2009	10 Mar 2010	0.49 现金
10 Nov 2009	19 Oct 2009	10 Dec 2009	0.49 现金
12 Aug 2009	22 Jun 2009	10 Sep 2009	0.49 现金
13 May 2009	20 Apr 2009	10 Jun 2009	0.49 现金
11 Feb 2009	15 Dec 2008	10 Mar 2009	0.49 现金
12 Nov 2008	20 Oct 2008	10 Dec 2008	0.47 现金
13 Aug 2008	20 Jun 2008	10 Sep 2008	0.47 现金
13 Feb 2008	17 Dec 2007	10 Mar 2008	0.47 现金
13 Nov 2007	15 Oct 2007	10 Dec 2007	0.425 现金
13 Aug 2007	21 Jun 2007	10 Sep 2007	0.425 现金
11 May 2007	16 Apr 2007	08 Jun 2007	0.425 现金
13 Feb 2007	18 Dec 2006	09 Mar 2007	0.425 现金
13 Nov 2006	16 Oct 2006	08 Dec 2006	0.4 现金
11 Aug 2006	26 Jun 2006	08 Sep 2006	0.4 现金
11 May 2006	24 Apr 2006	09 Jun 2006	0.4 现金
13 Feb 2006	19 Dec 2005	10 Mar 2006	0.4 现金
10 Nov 2005	17 Oct 2005	09 Dec 2005	0.38 现金
11 Aug 2005	24 Jun 2005	09 Sep 2005	0.38 现金
11 May 2005	18 Apr 2005	10 Jun 2005	0.38 现金
11 Feb 2005	20 Dec 2004	10 Mar 2005	0.38 现金
10 Nov 2004	18 Oct 2004	10 Dec 2004	0.355 现金
11 Aug 2004	28 Jun 2004	10 Sep 2004	0.355 现金
12 May 2004	19 Apr 2004	10 Jun 2004	0.355 现金
11 Feb 2004	15 Dec 2003	10 Mar 2004	0.355 现金
12 Nov 2003	20 Oct 2003	10 Dec 2003	0.335 现金
13 Aug 2003	23 Jun 2003	10 Sep 2003	0.335 现金
13 May 2003	28 Apr 2003	10 Jun 2003	0.335 现金
12 Feb 2003	16 Dec 2002	10 Mar 2003	0.335 现金
13 Nov 2002	21 Oct 2002	10 Dec 2002	0.31 现金
13 Aug 2002	24 Jun 2002	10 Sep 2002	0.31 现金
13 May 2002	15 Apr 2002	10 Jun 2002	0.31 现金
13 Feb 2002	17 Dec 2001	08 Mar 2002	0.31 现金
13 Nov 2001	15 Oct 2001	10 Dec 2001	0.28 现金
13 Aug 2001	25 Jun 2001	10 Sep 2001	0.28 现金
11 May 2001	16 Apr 2001	11 Jun 2001	0.28 现金
13 Feb 2001	18 Dec 2000	09 Mar 2001	0.28 现金
13 Nov 2000	16 Oct 2000	11 Dec 2000	0.26 现金
11 Aug 2000	26 Jun 2000	11 Sep 2000	0.26 现金
11 May 2000	17 Apr 2000	09 Jun 2000	0.26 现金
11 Feb 2000	20 Dec 1999	10 Mar 2000	0.26 现金
10 Nov 1999	18 Oct 1999	10 Dec 1999	0.23 现金
11 Aug 1999	19 Jul 1999	10 Sep 1999	0.23 现金
12 May 1999	19 Apr 1999	10 Jun 1999	0.23 现金
10 Feb 1999	21 Dec 1998	10 Mar 1999	0.23 现金
10 Nov 1998	20 Oct 1998	10 Dec 1998	0.2 现金
12 Aug 1998	20 Jul 1998	10 Sep 1998	0.2 现金
13 May 1998	20 Apr 1998	10 Jun 1998	0.2 现金
11 Feb 1998	15 Dec 1997	10 Mar 1998	0.2 现金
12 Nov 1997	15 Sep 1997	10 Dec 1997	0.2 现金
13 Aug 1997	21 Jul 1997	10 Sep 1997	0.36 现金
13 May 1997	21 Apr 1997	10 Jun 1997	0.36 现金
12 Feb 1997	16 Dec 1996	10 Mar 1997	0.36 现金
13 Nov 1996	21 Oct 1996	10 Dec 1996	0.3425 现金
13 Aug 1996	15 Jul 1996	10 Sep 1996	0.3425 现金
13 May 1996	15 Apr 1996	10 Jun 1996	0.3425 现金
13 Feb 1996	18 Dec 1995	11 Mar 1996	0.3425 现金
13 Nov 1995	17 Oct 1995	11 Dec 1995	0.685 现金
11 Aug 1995	17 Jul 1995	11 Sep 1995	0.645 现金
09 May 1995	17 Apr 1995	12 Jun 1995	0.645 现金
显示更多

每年股息收益率

年份	每年总股息 ($)	频率/年份	收益率 %
2025	1.50	1	0.20
2024	5.20	4	0.67
2023	4.52	4	0.78
2022	3.92	4	1.07
2021	3.40	4	1.23
2020	2.96	4	1.75
2019	2.58	4	1.96
2018	2.25	4	1.94
2017	2.08	4	2.46
2016	2.04	4	2.77
2015	2.00	4	2.37
2014	1.96	4	2.84
2013	1.96	4	3.84
2012	1.47	3	2.98
2011	1.96	4	4.72
2010	1.96	4	5.59
2009	1.96	4	5.49
2008	1.41	3	3.50
2007	1.70	4	3.18
2006	1.60	4	3.07
2005	1.52	4	2.69
2004	1.42	4	2.50
2003	1.34	4	1.91
2002	1.24	4	1.95
2001	1.12	4	1.43
2000	1.04	4	1.12
1999	0.920	4	1.38
1998	0.800	4	0.90
1997	1.28	4	1.84
1996	1.37	4	3.75
1995	1.98	3	7.02
显示更多

支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。

投资组合

请登录以添加到您的群组

AI 建议策略模板

自定义的价格提醒

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

请登录以添加到您的群组

已实现利润	-
未实现利润	-
收到股息 2025	-
利润总额	-
平均回报	-
数量(购买)	-
平均价格(购买)	-
数量(卖出)	-
平均价格(卖出)	-

请登录以添加到您的群组

没有符合您标准的股票

营业毛利率	23.51%
营业利益率 (TTM)	42.84%
稀释每股收益 (EPS TTM)	11.68
季度收入增长率 (YOY)	44.70%
季度盈利增长率 (YOY)	101.40%

总债务/股东权益 (D/E MRQ)	244.62%
流动比率 (MRQ)	1.15
营业现金流 (OCF TTM)	8.82 B
杠杆自由现金流 (LFCF TTM)	1.32 B

资产报酬率 (ROA TTM)	15.33%
股东权益报酬率 (ROE TTM)	84.26%

安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)